title: Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
abstract: OBJECTIVE
  To compare 24 h intraocular pressure (IOP) control obtained with preservative free (PF) tafluprost 0.0015% versus branded preservative containing latanoprost 0.005% administered as first choice monotherapy in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT).
  
  
  METHODS
  This prospective, observer-masked, crossover study included consecutive newly diagnosed patients with POAG or OHT, and baseline IOP between 24 and 33 mm Hg. Qualifying patients underwent baseline untreated 24 h IOP monitoring in habitual positions, with Goldmann tonometry at times 10:00, 14:00, 18:00 and 22:00, and Perkins supine tonometry at times 02:00 and 06:00. They were then randomised to either latanoprost or tafluprost, administered in the evening, for 3 months and then switched to the opposite therapy for another 3 months. 24 h monitoring was repeated at the end of each treatment period.
  
  
  RESULTS
  38 patients completed the study. Mean untreated 24 h IOP (24.9 mm Hg) was significantly reduced with both prostaglandins (p<0.001). Tafluprost demonstrated similar mean 24 h efficacy compared with latanoprost (17.8 vs 17.7 mm Hg; p=0.417). Latanoprost demonstrated significantly better 24 h trough IOP (15.9 vs 16.3 mm Hg; p=0.041) whereas tafluprost provided significantly lower 24 h IOP fluctuation (3.2 vs 3.8 mm Hg; p=0.008). No significant difference existed between the two prostaglandins for any adverse event.
  
  
  CONCLUSIONS
  PF tafluprost achieved similar 24 h IOP reduction to branded latanoprost. The current study highlights the importance of complete assessment of efficacy over 24 h.
  
  
  BACKGROUND
  NCT01162603.
authors.affiliation: Glaucoma Unit, 1st University Department of Ophthalmology, Aristotle University, AHEPA Hospital, , Thessaloniki, Greece.
authors.forename: Anastasios G P
authors.initials: AG
authors.lastname: Konstas
authors.forename: Luciano
authors.initials: L
authors.lastname: Quaranta
authors.forename: Andreas
authors.initials: A
authors.lastname: Katsanos
authors.forename: Ivano
authors.initials: I
authors.lastname: Riva
authors.forename: James C
authors.initials: JC
authors.lastname: Tsai
authors.forename: Theodoros
authors.initials: T
authors.lastname: Giannopoulos
authors.forename: Irini C
authors.initials: IC
authors.lastname: Voudouragkaki
authors.forename: Eleni
authors.initials: E
authors.lastname: Paschalinou
authors.forename: Irene
authors.initials: I
authors.lastname: Floriani
authors.forename: Anna-Bettina
authors.initials: AB
authors.lastname: Haidich
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D011310:Preservatives, Pharmaceutical / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D011460:Prostaglandins F / Q000008:administration & dosage* / Q000009:adverse effects; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D011310:Preservatives, Pharmaceutical; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; C485333:tafluprost; D000077338:Latanoprost
keywords: Clinical Trial; Drugs; Glaucoma; Intraocular pressure; Treatment Medical